Literature DB >> 20961087

DNA binding to an anticancer organo-ruthenium complex.

Marcelina Klajner1, Pascal Hebraud, Claude Sirlin, Christian Gaiddon, Sebastien Harlepp.   

Abstract

Because many anticancer drugs interact with DNA, the determination of their association constants to DNA is essential for quantifying their mechanisms of action. The interactions between a new ruthenium-derived compound [ruthenium(phenanthroline)(κ-C,N-(2-phenyl-pyridine)(NCMe)(2)]PF(6), called RDC11] and DNA are studied using different techniques. Fluorescent experiments are used to determine the association and dissociation constants under different salt concentrations. The binding is shown to be reversible and noncovalent. The association constants vary from 1.5 × 10(6) M(-1) to 2.9 × 10(3) M(-1) when increasing the sodium concentration from 0.1 to 200 mM. Single-molecule stretching methods are used to study the interaction of RDC with longer DNA strands (8.6 kbp home-built dimer of pBR322). The affinities of RDC with DNA under different loads are obtained using McGhee and von Hippel analysis. The affinity constant and thermodynamic parameters are in good agreement with the values found in the literature and lead to the conclusion that this molecule intercalates dsDNA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20961087     DOI: 10.1021/jp1044783

Source DB:  PubMed          Journal:  J Phys Chem B        ISSN: 1520-5207            Impact factor:   2.991


  6 in total

1.  DNA molecular recognition and cellular selectivity of anticancer metal(II) complexes of ethylenediaminediacetate and phenanthroline: multiple targets.

Authors:  Sze-Tin Von; Hoi-Ling Seng; Hong-Boon Lee; Seik-Weng Ng; Yusuke Kitamura; Makoto Chikira; Chew-Hee Ng
Journal:  J Biol Inorg Chem       Date:  2011-08-11       Impact factor: 3.358

2.  Light-Sensitive Ruthenium Complex-Loaded Cross-linked Polymeric Nanoassemblies for the Treatment of Cancer.

Authors:  M Dickerson; B Howerton; Y Bae; E Glazer
Journal:  J Mater Chem B       Date:  2015-12-01       Impact factor: 6.331

3.  Synthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexes.

Authors:  Marta Maroto-Díaz; Benelita T Elie; Pilar Gómez-Sal; Jorge Pérez-Serrano; Rafael Gómez; María Contel; F Javier de la Mata
Journal:  Dalton Trans       Date:  2016-04-28       Impact factor: 4.390

4.  Flexibility of short ds-DNA intercalated by a dipyridophenazine ligand.

Authors:  Fuchao Jia; Stéphane Despax; Jean-Pierre Münch; Pascal Hébraud
Journal:  Front Chem       Date:  2015-04-16       Impact factor: 5.221

5.  In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer.

Authors:  Malgorzata Frik; Alberto Martínez; Benelita T Elie; Oscar Gonzalo; Daniel Ramírez de Mingo; Mercedes Sanaú; Roberto Sánchez-Delgado; Tanmoy Sadhukha; Swayam Prabha; Joe W Ramos; Isabel Marzo; María Contel
Journal:  J Med Chem       Date:  2014-11-26       Impact factor: 7.446

6.  A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin.

Authors:  Cynthia Licona; Marie-Elodie Spaety; Antonelle Capuozzo; Moussa Ali; Rita Santamaria; Olivier Armant; Francois Delalande; Alain Van Dorsselaer; Sarah Cianferani; John Spencer; Michel Pfeffer; Georg Mellitzer; Christian Gaiddon
Journal:  Oncotarget       Date:  2017-01-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.